Insider Buying: DENTSPLY SIRONA (NASDAQ:XRAY) Director Purchases 9,985 Shares of Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Gladden acquired 9,985 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was bought at an average price of $10.02 per share, with a total value of $100,049.70. Following the transaction, the director directly owned 61,849 shares in the company, valued at $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

DENTSPLY SIRONA Trading Up 0.5%

XRAY stock traded up $0.05 during trading on Monday, hitting $10.14. The company had a trading volume of 2,937,234 shares, compared to its average volume of 4,807,820. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The firm has a 50-day moving average price of $10.98 and a 200-day moving average price of $11.71. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $17.09. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -3.22, a PEG ratio of 1.20 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The company had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. During the same quarter last year, the firm earned $0.43 EPS. The business’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, analysts predict that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Institutional Trading of DENTSPLY SIRONA

Several institutional investors and hedge funds have recently made changes to their positions in XRAY. Southpoint Capital Advisors LP bought a new stake in shares of DENTSPLY SIRONA during the 1st quarter valued at $116,000,000. AQR Capital Management LLC grew its holdings in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares during the period. Armistice Capital LLC grew its holdings in shares of DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after buying an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in shares of DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after buying an additional 4,003,606 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares during the period. Institutional investors own 95.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on XRAY shares. Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Mizuho dropped their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings cut shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Barrington Research upped their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Finally, Barclays dropped their target price on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research report on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $13.55.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.